Investor
SABBY MANAGEMENT, LLC
CIK 0001535610 · filed 2026-05-15 · SEC filing
13F book
$45.1M
Positions
22
13 new · 16 sold
Largest name
3.9%
Spdr S&P 500 Etf Tr
Est. mark
−$922.9K
Price effect on 9 names still held. Flow −$5.37M.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Spdr S&P 500 Etf Tr | — | 2.73K | $1.78M | 3.9% | −$10.6K | Added$1.55M |
| Alphaton Capital Corp | ALP | 2.07M | $654.8K | 1.5% | — | New |
| Briacell Therapeutics Corp | — | 380.7K | $392.1K | 0.9% | — | New |
| SenesTech, Inc. | SNES | 218.5K | $358.4K | 0.8% | −$105.3K | Added−$92.2K |
| Big Tree Cloud Hldgs Ltd | — | 137.6K | $337.1K | 0.7% | — | New |
| Briacell Therapeutics Corp | — | 73.9K | $309.7K | 0.7% | — | New |
| Token Cat Ltd | TC | 23.2K | $241.7K | 0.5% | — | New |
| Pop Culture Group Co., Ltd | CPOP | 664.4K | $201.1K | 0.4% | −$77.9K | Cut−$200.7K |
| Moleculin Biotech, Inc. | MBRX | 75K | $171.8K | 0.4% | — | New |
| Biodexa Pharmaceuticals Plc | BDRX | 257.5K | $159.1K | 0.4% | −$315K | Added−$273.7K |
| Arcadia Biosciences, Inc. | RKDA | 114.6K | $158.1K | 0.4% | — | New |
| TRX GOLD Corp | TRX | 100K | $150K | 0.3% | — | New |
| InMed Pharmaceuticals Inc. | INM | 220.3K | $142K | 0.3% | −$83.7K | Added−$71.7K |
| CanFite Biopharma Ltd ADR | — | 42.6K | $131.9K | 0.3% | — | New |
| China Sxt Pharmaceuticals In | — | 78.2K | $131.3K | 0.3% | — | New |
| Revelation Biosciences Inc | — | 99.4K | $119.3K | 0.3% | — | New |
| Calidi Biotherapeutics Inc | — | 434.9K | $103.9K | 0.2% | — | New |
| Bluejay Diagnostics, Inc. | BJDX | 28.7K | $52.9K | 0.1% | — | New |
| Lyra Therapeutics Inc | — | 104.1K | $51.1K | 0.1% | −$269.4K | Cut−$488.4K |
| Tempest Therapeutics, Inc. | TPST | 17.9K | $29.3K | 0.1% | −$22K | Cut−$483.3K |
| Briacell Therapeutics Corp | — | 206.8K | $28.9K | 0.1% | −$31.1K | Cut−$48.2K |
| Bnb Plus Corp. | BNBX | 13.5K | $8.67K | 0.0% | −$7.99K | Cut−$57.8K |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.